ATE526408T1 - Modulatoren von dem körpergewicht, entsprechende nukleinsaüre und proteine, und diagnostische und therapeutische anwendungen davon - Google Patents

Modulatoren von dem körpergewicht, entsprechende nukleinsaüre und proteine, und diagnostische und therapeutische anwendungen davon

Info

Publication number
ATE526408T1
ATE526408T1 AT95929591T AT95929591T ATE526408T1 AT E526408 T1 ATE526408 T1 AT E526408T1 AT 95929591 T AT95929591 T AT 95929591T AT 95929591 T AT95929591 T AT 95929591T AT E526408 T1 ATE526408 T1 AT E526408T1
Authority
AT
Austria
Prior art keywords
body weight
modulators
present
diagnostic
nucleic acids
Prior art date
Application number
AT95929591T
Other languages
English (en)
Inventor
Jeffrey FRIEDMAN
Yiying Zhang
Ricardo Proenca
Margherita Maffei
Jeffrey Halaas
Ketan Gajiwala
Stephen BURLEY
Original Assignee
Univ Rockefeller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23124262&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE526408(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/438,431 external-priority patent/US6429290B1/en
Priority claimed from US08/483,211 external-priority patent/US6309853B1/en
Application filed by Univ Rockefeller filed Critical Univ Rockefeller
Application granted granted Critical
Publication of ATE526408T1 publication Critical patent/ATE526408T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT95929591T 1994-08-17 1995-08-17 Modulatoren von dem körpergewicht, entsprechende nukleinsaüre und proteine, und diagnostische und therapeutische anwendungen davon ATE526408T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/292,345 US6001968A (en) 1994-08-17 1994-08-17 OB polypeptides, modified forms and compositions
US08/347,563 US5935810A (en) 1994-08-17 1994-11-30 Mammalian ob polypeptides capable of modulating body weight, corresponding nucleic acids, and diagnostic and therapeutic uses thereof
US08/438,431 US6429290B1 (en) 1994-08-17 1995-05-10 OB polypeptides, modified forms and derivatives
US08/483,211 US6309853B1 (en) 1994-08-17 1995-06-07 Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
PCT/US1995/010479 WO1996005309A2 (en) 1994-08-17 1995-08-17 Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof

Publications (1)

Publication Number Publication Date
ATE526408T1 true ATE526408T1 (de) 2011-10-15

Family

ID=23124262

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95929591T ATE526408T1 (de) 1994-08-17 1995-08-17 Modulatoren von dem körpergewicht, entsprechende nukleinsaüre und proteine, und diagnostische und therapeutische anwendungen davon

Country Status (11)

Country Link
US (8) US6001968A (de)
EP (1) EP2402444A1 (de)
CN (1) CN102002102A (de)
AT (1) ATE526408T1 (de)
CO (1) CO4410343A1 (de)
DK (1) DK0777732T3 (de)
IL (2) IL188522A0 (de)
LT (1) LT4265B (de)
PT (1) PT777732E (de)
SI (1) SI0777732T1 (de)
ZA (1) ZA956868B (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6946257B1 (en) 1994-10-07 2005-09-20 Regents Of The University Of California Patched genes and uses related thereto
US6429354B1 (en) 1994-10-07 2002-08-06 The Board Of Trustees Of The Leland Stanford Junior University Patched genes and uses related thereto
EP1616942A3 (de) 1994-10-07 2006-11-22 The Board Of Trustees Of The Leland Stanford Junior University Patched Gene und ihre Verwendung
US6936439B2 (en) * 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US20030040467A1 (en) * 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6977240B1 (en) * 1995-11-27 2005-12-20 Millenium Pharmaceuticals, Inc. Methods of using the OB receptor antibodies to treat bodyweight disorders
US6620413B1 (en) * 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
US6541604B1 (en) * 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
US20050019325A1 (en) * 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
US7067472B1 (en) 1996-06-04 2006-06-27 The Scripps Research Institute Diagnostic and therapeutic methods related to regulating energy mobilization with OB protein and OB antibodies
US6277592B1 (en) * 1996-07-31 2001-08-21 Purina Mills, Inc. Porcine leptin protein, nucleic acid sequences coding therefor and uses thereof
US6297027B1 (en) 1996-07-31 2001-10-02 Purina Mills, Inc. Bovine leptin protein, nucleic acid sequences coding therefor and uses thereof
JP2001500869A (ja) * 1996-09-20 2001-01-23 ヘキスト、アクチェンゲゼルシャフト 第ii種糖尿病におけるインスリン耐性を治療するためのレプチンアンタゴニストの使用
US6777388B1 (en) * 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
US6420339B1 (en) * 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US20030215423A1 (en) * 1999-04-01 2003-11-20 Merck & Co., Inc. Gene therapy for obesity
AU767068B2 (en) * 1999-06-11 2003-10-30 Baylor College Of Medicine Methods and compositions for control of bone formation via modulation of leptin activity
AU782230B2 (en) * 1999-09-22 2005-07-14 Serono Genetics Institute S.A. Methods of screening for compounds that modulate the LSR-leptin interaction and their use in the prevention and treatment of obesity-related diseases
US8110218B2 (en) * 2000-11-30 2012-02-07 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic protein-lipid complexes
AU2002248190A1 (en) * 2000-11-30 2002-08-12 The Research Foundation Of State University Of New York Method of complexing a protein by the use of a dispersed system and proteins thereof
US7625584B2 (en) * 2000-11-30 2009-12-01 The Research Foundation Of State University Of New York Method of complexing a protein by the use of a dispersed system and proteins thereof
US20020132982A1 (en) * 2000-11-30 2002-09-19 Balasubramanian Sathyamangalam V. AHF associated dispersion system and method for preparation
US6869766B2 (en) * 2000-12-22 2005-03-22 The Regents Of The University Of California Gene associated with regulation of adiposity and insulin response
US7054758B2 (en) * 2001-01-30 2006-05-30 Sciona Limited Computer-assisted means for assessing lifestyle risk factors
US7329725B1 (en) * 2003-10-29 2008-02-12 Nastech Pharmaceutical Company Inc. Phage displayed Trp cage ligands
US20090233986A1 (en) * 2004-07-27 2009-09-17 Mount Sinai School Of Medicine Methods and compositions for using sax2
ES2258923B1 (es) * 2005-02-23 2007-11-01 Universitat De Les Illes Balears Uso de la leptina para la prevencion del exceso de peso corporal y composicion que contiene leptina.
US8227408B2 (en) * 2005-09-07 2012-07-24 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
KR100763251B1 (ko) * 2006-02-01 2007-10-04 삼성전자주식회사 웨이퍼 이송 장치
US20090136465A1 (en) 2007-09-28 2009-05-28 Intrexon Corporation Therapeutic Gene-Switch Constructs and Bioreactors for the Expression of Biotherapeutic Molecules, and Uses Thereof
KR20110028457A (ko) * 2008-05-21 2011-03-18 뉴로테즈 인코포레이티드 신경섬유 매듭과 연관된 신경변성 장애를 치료하는 방법
WO2009149379A2 (en) * 2008-06-05 2009-12-10 Regents Of The University Of Michigan Use of leptin for the treatment of fatty liver diseases and conditions
CA2742600A1 (en) * 2008-11-04 2010-05-14 Nikolaos Tezapsidis Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amlyoid beta
MX349054B (es) 2010-09-28 2017-07-07 Aegerion Pharmaceuticals Inc Leptinas altamente solubles.
CN111529535A (zh) 2012-09-27 2020-08-14 儿童医学中心公司 用于治疗肥胖症的化合物和其使用方法
CN102925468A (zh) * 2012-09-28 2013-02-13 长春长理康源生物技术有限公司 小鼠肝脏羧酸酯酶基因克隆表达
PT3074033T (pt) 2013-11-26 2019-02-08 Childrens Medical Ct Corp Compostos para o tratamento de obesidade e métodos de utilização dos mesmos
US20170209408A1 (en) 2014-04-03 2017-07-27 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
CN105132566A (zh) * 2015-09-21 2015-12-09 上海中优生物高科技有限责任公司 毒素堆积型肥胖基因个体化干预饮品的制备方法及其系统
DK3509624T3 (da) 2016-09-12 2023-11-13 Amryt Pharmaceuticals Inc Fremgangsmåder til detektering af anti-leptin-neutraliserende antistoffer
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
CN111200641B (zh) * 2019-12-25 2022-06-21 深圳供电局有限公司 数据跨链共享方法、系统,计算机设备和存储介质
CN115368441B (zh) * 2022-09-21 2025-06-13 湖北省农业科学院农产品加工与核农技术研究所 一种高效降血压水产品活性肽的制备方法
JP2026500309A (ja) * 2022-12-14 2026-01-06 ユニヴェルシテ・ドゥ・ボルドー ミエロペルオキシダーゼ活性及びグルコースオキシダーゼ活性を含む人工二機能性酵素及びその適用

Family Cites Families (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US31006A (en) * 1861-01-01 Feeding mechanism for spoke-machines
USRE31006E (en) 1968-09-24 1982-08-03 Akzona Incorporated Process for the demonstration and determination of reaction components having specific binding affinity for each other
US3654090A (en) * 1968-09-24 1972-04-04 Organon Method for the determination of antigens and antibodies
US3650090A (en) * 1970-06-19 1972-03-21 Phillips Petroleum Co Analysis of gaseous mixtures
NL154598B (nl) * 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4016043A (en) * 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4491632A (en) * 1979-10-22 1985-01-01 The Massachusetts General Hospital Process for producing antibodies to hepatitis virus and cell lines therefor
US4444887A (en) * 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4342566A (en) * 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
DE3167442D1 (en) * 1980-07-07 1985-01-10 Nat Res Dev Improvements in or relating to cell lines
US4341761A (en) * 1980-07-25 1982-07-27 E. I. Du Pont De Nemours And Company Antibodies to immunogenic peptides and their use to purify human fibroblast interferon
US4466917A (en) * 1981-02-12 1984-08-21 New York University Malaria vaccine
US4493890A (en) * 1981-03-23 1985-01-15 Miles Laboratories, Inc. Activated apoglucose oxidase and its use in specific binding assays
US4451570A (en) * 1981-03-26 1984-05-29 The Regents Of The University Of California Immunoglobulin-secreting human hybridomas from a cultured human lymphoblastoid cell line
US4399121A (en) * 1981-11-04 1983-08-16 Miles Laboratories, Inc. Iodothyronine immunogens and antibodies
US4427783A (en) * 1981-12-14 1984-01-24 Hoffmann-La Roche Inc. Immunoassay of thymosin α1
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4650764A (en) * 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US4631211A (en) * 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
US4925673A (en) * 1986-08-18 1990-05-15 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents encapsulated with proteinoids
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5071773A (en) * 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
US4980289A (en) * 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
US4981784A (en) * 1987-12-02 1991-01-01 The Salk Institute For Biological Studies Retinoic acid receptor method
US5010175A (en) * 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
EP0719860B1 (de) 1988-05-13 2009-12-16 Amgen Inc. Verfahren zur Isolierung und Reinigung von G-CSF
IL91765A0 (en) * 1988-09-26 1990-06-10 Salk Inst Biotech Ind Mixed feed recombinant yeast fermentation
US5102789A (en) * 1989-03-15 1992-04-07 The Salk Institute Biotechnology/Industrial Associates, Inc. Production of epideramal growth factor in pichia pastoris yeast cells
EP0401384B1 (de) * 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemisch modifizierte granulocytenkolonie erregender faktor
US5124263A (en) * 1989-01-12 1992-06-23 Wisconsin Alumni Research Foundation Recombination resistant retroviral helper cell and products produced thereby
US5098833A (en) 1989-02-23 1992-03-24 Genentech, Inc. DNA sequence encoding a functional domain of a lymphocyte homing receptor
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5354844A (en) * 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
CH679945A5 (de) 1989-04-04 1992-05-15 Oetiker Hans Maschinen
WO1990014092A1 (en) * 1989-05-18 1990-11-29 Cell Genesys, Inc. Single-strand site-directed modification of mammalian genes in vivo
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
SG88714A1 (en) * 1989-11-06 2002-05-21 Cell Genesys Inc Production of proteins using homologous recombination
DE779362T1 (de) * 1989-12-22 2001-04-05 Applied Research Systems Ars Holding N.V., Curacao DNS-Konstrukten zur Aktivierung und Veränderung der Expression von endogenen Genen
FR2658841B1 (fr) 1990-02-26 1993-06-11 Aerospatiale Procede et dispositif pour la realisation d'elements d'armature composes de fibres resistantes.
US5139749A (en) * 1990-06-22 1992-08-18 Tas, Inc. Fluidized calcining process
JPH04257973A (ja) * 1991-02-13 1992-09-14 Hitachi Ltd 設計支援装置及び設計支援方法
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
JP3507486B2 (ja) * 1991-03-15 2004-03-15 アムジエン・インコーポレーテツド 顆粒球コロニー刺激因子の肺内投与
US5268295A (en) 1991-05-31 1993-12-07 W. Alton Jones Cell Science Center, Inc. Mammalian adipocyte protein p154, nucleic acids coding therefor and uses thereof
ZA924674B (en) 1991-07-02 1993-04-28 Imclone Systems Inc Cysteine depleted il-6 mutein
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
FI931701A7 (fi) * 1992-04-17 1993-10-18 Sankyo Co Rasvan muodostumista ehkäisevän tekijän johdannaiset, niiden valmistus ja käyttö
ATE311895T1 (de) 1992-05-26 2005-12-15 Immunex Corp Neue zytokine die cd30 binden
WO1994000558A1 (en) * 1992-06-19 1994-01-06 Joslin Diabetes Center, Inc. DIABETOGENE rad: A TYPE II DIABETES SPECIFIC GENE
PT669929E (pt) 1992-11-13 2007-04-30 Immunex Corp Ligando de elk, uma citoquina
TW334433B (en) 1992-12-09 1998-06-21 Takeda Pharm Industry Co Ltd Crystalline salt of (S)-(+)-5-amino-2,4,6,7-tetramethyl-2-(4-phenylpiperidinomethyl)-2,3-dihydrobenzo(b)furan dihydrochloride their production and use
EP0601417A3 (de) * 1992-12-11 1998-07-01 Hoechst Aktiengesellschaft Physiologisch verträglicher und physiologisch abbaubarer, Kohlenhydratrezeptorblocker auf Polymerbasis, ein Verfahren zu seiner Herstellung und seine Verwendung
US5641672A (en) 1993-06-09 1997-06-24 The Trustees Of Columbia University In The City Of New York Cloning and uses of the genetic locus bcl-6
AU7477394A (en) * 1993-07-30 1995-03-27 University Of Medicine And Dentistry Of New Jersey Efficient gene transfer into primary lymphocytes
US5575705A (en) 1993-08-12 1996-11-19 Church & Dwight Co., Inc. Slurry blasting process
US5874075A (en) 1993-10-06 1999-02-23 Amgen Inc. Stable protein: phospholipid compositions and methods
DE69521880T2 (de) 1994-02-08 2002-01-03 Amgen Inc., Thousand Oaks Orales verabreichungssystem von chemischmodifizierten proteinen g-csf
DE4411065A1 (de) 1994-03-30 1995-10-05 Bayer Ag Kationische Thiadiazol-Farbstoffe
JPH09508140A (ja) 1994-07-22 1997-08-19 エフ・ホフマン−ラ ロシュ アーゲー キメラtnf結合タンパク質を含有する医薬組成物
CZ25697A3 (en) 1994-07-29 1997-09-17 Smithkline Beecham Plc Novel compounds
US5574018A (en) 1994-07-29 1996-11-12 Amgen Inc. Conjugates of vitamin B12 and proteins
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5861485A (en) * 1994-08-23 1999-01-19 Millennium Pharmaceuticals, Inc. Polypeptides involved in body weight disorders, including obesity
US5643748A (en) * 1994-09-14 1997-07-01 Progenitor, Inc. HU-B1.219, a novel human hematopoietin receptor
US5912123A (en) * 1994-09-14 1999-06-15 Progenitor, Inc. Detection of the leptin receptor in reproductive organs and methods for regulating reproductive biology
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
CA2205572A1 (en) 1994-12-12 1996-06-20 Beth Israel Hospital Association Chimeric cytokines and uses thereof
US5858967A (en) * 1995-01-20 1999-01-12 University Of Washington Appetite supression factor and related methods
US5827734A (en) 1995-01-20 1998-10-27 University Of Washington Materials and methods for determining ob protein in a biological sample
US5563244A (en) * 1995-01-31 1996-10-08 Eli Lilly And Company Anti-obesity proteins
US5569743A (en) * 1995-01-31 1996-10-29 Eli Lilly And Company Anti-obesity proteins
US5552522A (en) * 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5532336A (en) * 1995-01-31 1996-07-02 Eli Lilly And Company Anti-obesity proteins
US5605886A (en) * 1995-01-31 1997-02-25 Eli Lilly And Company Anti-obesity proteins
US5525705A (en) * 1995-01-31 1996-06-11 Eli Lilly And Company Anti-obesity proteins
US5552523A (en) * 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5563243A (en) * 1995-01-31 1996-10-08 Eli Lilly And Company Anti-obesity proteins
US5691309A (en) * 1995-01-31 1997-11-25 Eli Lilly And Company Anti-obesity proteins
US5594104A (en) * 1995-01-31 1997-01-14 Eli Lilly And Company Anti-obesity proteins
US5574133A (en) * 1995-01-31 1996-11-12 Eli Lilly And Company Anti-obesity proteins
US5559208A (en) * 1995-01-31 1996-09-24 Eli Lilly And Company Anti-obesity proteins
EP0725079A1 (de) * 1995-01-31 1996-08-07 Eli Lilly And Company Proteine gegen die Fettleibigkeit
US5554727A (en) * 1995-01-31 1996-09-10 Eli Lilly And Company Anti-obesity proteins
JPH11501297A (ja) * 1995-01-31 1999-02-02 イーライ・リリー・アンド・カンパニー 抗肥満症タンパク質
US5567803A (en) * 1995-01-31 1996-10-22 Eli Lilly And Company Anti-obesity proteins
US5580954A (en) * 1995-01-31 1996-12-03 Eli Lilly And Company Anti-obesity proteins
US5567678A (en) * 1995-01-31 1996-10-22 Eli Lilly And Company Anti-obesity proteins
WO1996023815A1 (en) * 1995-01-31 1996-08-08 Eli Lilly And Company Ob gene product antibodies
US5521283A (en) * 1995-01-31 1996-05-28 Eli Lilly And Company Anti-obesity proteins
US5569744A (en) * 1995-01-31 1996-10-29 Eli Lilly And Company Anti-obesity proteins
US5552524A (en) * 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5563245A (en) * 1995-01-31 1996-10-08 Eli Lilly And Company Anti-obesity proteins
AU4862396A (en) * 1995-02-06 1996-08-27 Eli Lilly And Company Human obesity gene
US5594101A (en) * 1995-03-03 1997-01-14 Eli Lilly And Company Anti-obesity proteins
US5719266A (en) 1995-03-17 1998-02-17 Eli Lilly And Company Anti-obesity proteins
US6068976A (en) * 1995-03-20 2000-05-30 Ligand Pharmaceuticals Incorporated Modulators of ob gene and screening methods therefor
JPH08333394A (ja) * 1995-04-03 1996-12-17 Takeda Chem Ind Ltd ラット肥満遺伝子、その遺伝子産物およびその製造法
EP0736599A3 (de) * 1995-04-03 1996-12-11 Takeda Chemical Industries Ltd Das Obesitätsgen der Ratte, sein Genprodukt und dessen Herstellung
AU5539596A (en) * 1995-04-06 1996-10-23 Amylin Pharmaceuticals, Inc. Anti-obesity agents
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5614379A (en) * 1995-04-26 1997-03-25 Eli Lilly And Company Process for preparing anti-obesity protein
GB9509164D0 (en) * 1995-05-05 1995-06-28 Smithkline Beecham Plc Novel compounds
ES2093593T1 (es) * 1995-05-05 1997-01-01 Hoffmann La Roche Proteinas obesas (ob) recombinantes.
EP0826045A1 (de) * 1995-05-08 1998-03-04 Chiron Corporation Nukleinsäuren zur behandlung von feltsucht
ZA963915B (en) * 1995-05-19 1997-11-17 Lilly Co Eli Obesity gene product.
US5766851A (en) * 1995-05-19 1998-06-16 The Johns Hopkins University School Of Medicine Susceptibility gene for obesity and type II diabetes mellitus
CA2221824A1 (en) * 1995-05-26 1996-11-28 Eli Lilly And Company Rhesus ob protein and dna
JPH11505725A (ja) * 1995-05-30 1999-05-25 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 肥満タンパク質の効果を調節する化合物の検出方法
CA2222073A1 (en) * 1995-06-01 1996-12-05 Charles Merritt Beasley Jr. Method for treating anorexia
US5849708A (en) 1995-06-06 1998-12-15 Joslin Diabetes Center, Inc. Promotion of eating behavior
IT1278696B1 (it) * 1995-06-07 1997-11-27 Edi Bondioli Componente tubolare per alberi di trasmissione telescopici
WO1996040912A1 (en) * 1995-06-07 1996-12-19 Amgen Inc. Ob protein compositions and method
GB9511935D0 (en) * 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound
AU705368B2 (en) * 1995-06-22 1999-05-20 Bayer Aktiengesellschaft Pesticidal tris-oximino heterocyclic compounds
AU695934B2 (en) * 1995-06-30 1998-08-27 Eli Lilly And Company Methods for treating diabetes
EP0759441A3 (de) * 1995-06-30 1999-06-30 Eli Lilly And Company Verfahren zur Behandlung von mit Neuropeptid Y assozierten Zuständen
WO1997006816A1 (en) * 1995-08-17 1997-02-27 Amgen Inc. Methods of reducing or maintaining reduced levels of blood lipids using ob protein compositions
AU7072896A (en) * 1995-09-19 1997-04-09 Eli Lilly And Company Dna encoding medicinal proteins
AUPN564195A0 (en) * 1995-09-26 1995-10-19 Walter And Eliza Hall Institute Of Medical Research, The A novel haemopoietin receptor and genetic sequences encoding same
ATE243998T1 (de) * 1995-10-12 2003-07-15 Supergen Inc Liposomformulierung von 5-beta steroiden
AU7522496A (en) * 1995-10-25 1997-05-15 Regents Of The University Of California, The Methods for restoring or enhancing reproductive function in reproductively impaired hosts
AU7484596A (en) * 1995-11-01 1997-05-22 Merck & Co., Inc. Combination therapy for the treatment of diabetes and obesity
WO1997016550A1 (en) * 1995-11-02 1997-05-09 Bristol-Myers Squibb Company Polypeptide fragments derived from the obese gene product
US5698389A (en) * 1995-11-16 1997-12-16 Tularik, Inc. Transcriptional promoter of the murine obesity gene
EP0869784B1 (de) * 1995-11-17 2005-08-31 The Johns Hopkins University Hemmung der fettsäuresynthase als mittel zur verminderung der adipozytenmenge
CA2236163A1 (en) * 1995-11-22 1997-05-29 Amgen Inc. Methods of increasing lean tissue mass using ob protein compositions
US6482927B1 (en) * 1995-11-27 2002-11-19 Millennium Pharmaceuticals, Inc. Chimeric proteins comprising the extracellular domain of murine Ob receptor
WO1997020933A2 (en) * 1995-12-06 1997-06-12 Schering Corporation MUTATIONAL VARIANTS OF MAMMALIAN Ob GENE PROTEINS
IL124831A0 (en) * 1995-12-27 1999-01-26 Genentech Inc Ob protein derivatives having prolonged half-life
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
NZ534416A (en) * 1996-01-04 2005-12-23 Amgen Inc OB protein receptor and related compositions and methods
AU721129B2 (en) * 1996-01-08 2000-06-22 Genentech Inc. WSX receptor and ligands
US7063958B1 (en) * 1996-01-16 2006-06-20 The Rockefeller University Nucleic acids db, the receptor for leptin
AU1833197A (en) * 1996-01-18 1997-08-11 Progenitor, Inc. Detection of a leptin receptor variant and methods for regulating obesity
WO1997026011A1 (en) * 1996-01-19 1997-07-24 Eli Lilly And Company Obesity protein formulations
JP2000504319A (ja) * 1996-01-19 2000-04-11 イーライ・リリー・アンド・カンパニー 肥満症タンパク質製剤
JP2000505079A (ja) * 1996-01-19 2000-04-25 イーライ・リリー・アンド・カンパニー 肥満症タンパク質製剤
EP0784981A3 (de) * 1996-01-19 1999-03-03 Eli Lilly And Company Formulierungen des Obesitätsproteins
AU731685C (en) * 1996-01-23 2002-08-22 Indevus Pharmaceuticals, Inc. Methods for using the obese gene and its gene product to stimulate hematopoietic development
US5831017A (en) * 1996-01-25 1998-11-03 Eli Lilly And Company Obesity protein analog compounds and formulations thereof
AU1838797A (en) * 1996-02-06 1997-08-28 Eli Lilly And Company Obesity protein compounds and formulations thereof
WO1997031015A1 (en) * 1996-02-22 1997-08-28 Merck & Co., Inc. Rat ob receptors and nucleotides encoding them
EP0912739A2 (de) * 1996-03-01 1999-05-06 Amgen Inc. Zusammensetzungen und methoden mit dem hunde-protein ob
JP2000509018A (ja) * 1996-03-26 2000-07-18 イーライ・リリー・アンド・カンパニー 肥満タンパク質製剤
AU2670897A (en) * 1996-04-04 1997-10-29 Amgen, Inc. Fibulin pharmaceutical compositions and related methods
CA2252443A1 (en) * 1996-04-22 1997-10-30 Merck & Co., Inc. Leptin assay
AU2408397A (en) * 1996-04-30 1997-11-19 Otsuka Pharmaceutical Co., Ltd. Ob protein receptor genes and use of the same
JP2000512486A (ja) * 1996-05-06 2000-09-26 メルク エンド カンパニー インコーポレーテッド Obレセプターイソ型及びそれらをコードする核酸
GB9610195D0 (en) 1996-05-15 1996-07-24 Medical Res Council Assay
BR9709529A (pt) 1996-06-06 1999-08-10 Smithkline Beecham P L C Socie Fragmentos de leptina (proteína ob)
AU3640397A (en) * 1996-06-07 1998-01-05 Eli Lilly And Company Ob protein binding protein
US6001816A (en) 1996-06-20 1999-12-14 Merck & Co., Inc. Gene therapy for leptin deficiency
US9002545B2 (en) 2011-01-07 2015-04-07 Wabtec Holding Corp. Data improvement system and method

Also Published As

Publication number Publication date
US8173793B2 (en) 2012-05-08
IL162093A (en) 2008-03-20
US6703493B1 (en) 2004-03-09
US6734160B2 (en) 2004-05-11
US20090318677A1 (en) 2009-12-24
LT97020A (en) 1997-09-25
US7994301B2 (en) 2011-08-09
IL188522A0 (en) 2008-04-13
LT4265B (en) 1997-12-29
US5935810A (en) 1999-08-10
US20040214214A1 (en) 2004-10-28
SI0777732T1 (sl) 2012-01-31
CO4410343A1 (es) 1997-01-09
US20030040039A1 (en) 2003-02-27
CN102002102A (zh) 2011-04-06
US7521258B2 (en) 2009-04-21
PT777732E (pt) 2012-01-09
EP2402444A1 (de) 2012-01-04
US7544492B1 (en) 2009-06-09
ZA956868B (en) 1996-04-09
US20110218332A1 (en) 2011-09-08
DK0777732T3 (da) 2012-01-09
US6001968A (en) 1999-12-14

Similar Documents

Publication Publication Date Title
DK0777732T3 (da) Modulatorer af kropsvægt, tilsvarende nukleinsyrer og proteiner og diagnostiske og terapeutiske anvendelser deraf
MX9701200A (es) Moduladores de peso del cuerpo, acidos nucleicos y proteinas correspondientes y sus usos en diagnostico y terapeuticos.
CN112195164B (zh) 工程化的Cas效应蛋白及其使用方法
Biswas et al. Mechanism of DnaB helicase of Escherichia coli: structural domains involved in ATP hydrolysis, DNA binding, and oligomerization
ES2153395T3 (es) Polimerasa termoestable del acido nucleico.
BR9712348A (pt) molécula de polinucleotídeo isolada, vetor de expressão, célula cultivada em que foi introduzido um vetor de expressão, processo para produzir um polipeptídeo homólogo de fgf, polipeptídeo homólogo de fgf isolado,composição farmacêutica, anticorpo, processos para estimular ex vivo células progenitoras de miócitos, e, paraliberar um agente ou droga seletivamente para o tecido do coração.
CA2091102A1 (en) Microsomal triglyceride transfer protein
IE911914A1 (en) Novel neurotropic growth factors comprising a homeobox¹peptide
WO2023178280A2 (en) Compositions and methods for modulating alpha-synuclein expression
ATE212060T1 (de) Vom desmingen abstammende amplifizierungssequenzen, vektoren, die diese enthalten und anwendungen derselben zur herstellung von proteinen
JO1694B1 (en) New chemical products
Lars et al. The human lα1 and lα2 germline promoter elements: proximal positive and distal negative elements may regulate the tissue specific expression of Cα1 and Cα2 germline transcripts
RU92016526A (ru) Белки, днк, векторы, фармацевтические композиции, применение белков, композиция детского питания, способы получения фармацевтической композиции и композиции для детского питания
Prinz et al. Alternative splicing of mouse IL-15 is due to the use of an internal splice site in exon 5
WO2000005373A3 (en) Methods and compositions for the diagnosis and treatment of body weight disorders, including obesity
WO2006066247A2 (en) Methods and compositions for extending telomere length and increasing cell lifespan
UA70911C2 (uk) Поліпептид ожиріння (варіанти), відповідні нуклеїнові кислоти (варіанти) та фармацевтична композиція
DK0870044T3 (da) Reguleret proteinekspression i stabilt transfekterede pattedyrsceller
Denarier et al. PCR cloning and sequence of the murine GPIIb gene promoter
Lee et al. Selection of a cDNA clone for chicken high-mobility-group 1 (HMG1) protein through its unusually conserved 3′-untranslated region, and improved expression of recombinant HMG1 in Escherichia coli
WO1999004825A8 (en) Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders
US20210310011A1 (en) The gene therapy dna vector gdtt1.8nas12 and the method for obtaining thereof
EP1270739B1 (de) Modulierte sekretierte alkalische Phosphatase (SEAP) Reporter Gene und Polypeptide
US20030186905A1 (en) Cis-acting regulatory nucleic acid sequences in the parathyroid hormone3' -untranslated region
WO2002097092A1 (en) Neuronal cell-specific promoter

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0777732

Country of ref document: EP